Literature DB >> 26401694

Studies of Polymorphism of Amyloid-β42 Peptide from Different Suppliers.

Mariya Yu Suvorina1, Olga M Selivanova1, Elizaveta I Grigorashvili1, Alexey D Nikulin1, Victor V Marchenkov1, Alexey K Surin1,2, Oxana V Galzitskaya1.   

Abstract

The aim of this study was to investigate the process of amyloidogenesis of amyloid-β (Aβ)42 peptide, by means of fluorescence spectroscopy, electron microscopy, X-ray diffraction, and mass spectrometry. It has been repeatedly reported in the literature that the process of fibril formation by Aβ42 peptide depends considerably not only upon the specific conditions (ionic conditions, pH, temperature, mixing, etc.), as well as the manufacturing route (synthetic or recombinant), but also on the methods of synthesis and purification. We have, for the first time, systematically analyzed samples of Aβ42 peptide supplied by five different companies (Anaspec, Invitrogen, Enzo, Sigma-Aldrich, and SynthAssist) and obtained evidence of significant variability, including lot to lot variations. All studied samples formed amyloid-like fibrils at pH3-6, and the fibrils contained cross-β structures. Samples from Anaspec, Invitrogen, and Enzo formed one particular type of amyloid-like fibrils, while the samples from Sigma-Aldrich and SynthAssist formed another distinct type of fibrils. The observed polymorphism emphasizes the capacity of the Aβ42 peptide to act as a prion agent with varying structural characteristics. The presented data have allowed us to propose a possible mechanism of formation of amyloid-like fibrils.

Entities:  

Keywords:  Alzheimer’s disease; Aβzzm32199042 peptide; amyloid fibril; electron microscopy; mass spectroscopy; oligomer; prion-like behavior; protofibril

Mesh:

Substances:

Year:  2015        PMID: 26401694     DOI: 10.3233/JAD-150147

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  Assessing Reproducibility in Amyloid β Research: Impact of Aβ Sources on Experimental Outcomes.

Authors:  Alejandro R Foley; Jevgenij A Raskatov
Journal:  Chembiochem       Date:  2020-05-05       Impact factor: 3.164

2.  RNA recognition motifs of disease-linked RNA-binding proteins contribute to amyloid formation.

Authors:  Sashank Agrawal; Pan-Hsien Kuo; Lee-Ya Chu; Bagher Golzarroshan; Monika Jain; Hanna S Yuan
Journal:  Sci Rep       Date:  2019-04-16       Impact factor: 4.379

3.  Ion mobility spectrometry combined with multivariate statistical analysis: revealing the effects of a drug candidate for Alzheimer's disease on Aβ1-40 peptide early assembly.

Authors:  Serena Lazzaro; Nina Ogrinc; Lieke Lamont; Graziella Vecchio; Giuseppe Pappalardo; Ron M A Heeren
Journal:  Anal Bioanal Chem       Date:  2019-08-12       Impact factor: 4.142

Review 4.  Medicinal Herbs and Their Derived Ingredients Protect against Cognitive Decline in In Vivo Models of Alzheimer's Disease.

Authors:  Yueh-Ting Tsai; Shung-Te Kao; Chin-Yi Cheng
Journal:  Int J Mol Sci       Date:  2022-09-25       Impact factor: 6.208

5.  Should the Treatment of Amyloidosis Be Personified? Molecular Mechanism of Amyloid Formation by Aβ Peptide and Its Fragments.

Authors:  Oxana V Galzitskaya; Alexey K Surin; Anna V Glyakina; Vadim V Rogachevsky; Olga M Selivanova
Journal:  J Alzheimers Dis Rep       Date:  2018-10-24

6.  New Model for Stacking Monomers in Filamentous Actin from Skeletal Muscles of Oryctolagus cuniculus.

Authors:  Anna V Glyakina; Alexey K Surin; Sergei Yu Grishin; Olga M Selivanova; Mariya Yu Suvorina; Liya G Bobyleva; Ivan M Vikhlyantsev; Oxana V Galzitskaya
Journal:  Int J Mol Sci       Date:  2020-11-06       Impact factor: 5.923

7.  Identification of Amyloidogenic Regions in Pseudomonas aeruginosa Ribosomal S1 Protein.

Authors:  Sergei Y Grishin; Ulyana F Dzhus; Anatoly S Glukhov; Olga M Selivanova; Alexey K Surin; Oxana V Galzitskaya
Journal:  Int J Mol Sci       Date:  2021-07-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.